摘要:
Disclosed are compounds having the formula: wherein R21 is an alkyl, aryl, alkoxy, hydroxy, or amino group or a halogen atom; wherein R2 is hydrogen or an alkyl, aryl, alkoxy, or amino group; wherein R23 and R24 are independently selected from hydrogen, an alkyl, aryl, alkoxy, hydroxy, or amino group, and a halogen atom or wherein R23 and R24, taken together with the carbon atom to which they are bound, form a ring; wherein R25 is hydrogen, an alkyl, aryl, alkoxy, hydroxy, or O-silyl group or a halogen atom; wherein Z, taken together with the carbons to which it is bonded, forms a 5-12 membered ring; and wherein Y is an electron withdrawing group. These compounds can be used to prepare erogorgiaene congeners, such as erogorgiaene, pseudopterosin A, helioporin E, pseudopteroxazole, colombiasin A, elisapoterosin B, elisabethadione, p-benzoquinone natural products, ileabethin, sinulobtain B, sinulobtain C, and sinulobtain D.
摘要:
Disclosed is method for increasing the efficiency of a dirhodium catalyst. The method includes providing a dirhodium catalyst, providing an organic ester, and contacting the dirhodium catalyst and the organic ester under conditions effective to increase the efficiency of the dirhodium catalyst. The organic ester is selected such that it is not a substrate for catalysis by the dirhodium catalyst. Dirhodium catalyst compositions which include a dirhodium catalyst and an organic ester are also disclosed. In these compositions, the organic ester is not a substrate for catalysis by the dirhodium catalyst. The method and compositions can be used in a number of reactions, including insertion reactions (e.g., C—H insertions, Si—H insertions, O—H insertions, and N—H insertions) cyclopropanation reactions, annulations (e.g., [3+2] annulations and [3+4] annulations), and ω,ω-diarylalkanoate syntheses.
摘要:
Disclosed are dirhodium catalyst compositions. One such dirhodium catalyst composition includes a dirhodium catalyst and a solid support. The dirhodium catalyst includes a Rh—Rh moiety and four bridging ligand moieties. The dirhodium catalyst and the solid support are bound together, but they are not covalently bound together via one or more of the bridging ligand moieties. Another such dirhodium catalyst composition includes a dirhodium tetracarboxylate catalyst and a solid support, and the dirhodium tetracarboxylate catalyst and the solid support are bound together. Yet another such dirhodium catalyst composition includes a dirhodium catalyst and a solid support, where the dirhodium catalyst includes a Rh—Rh moiety and where the dirhodium catalyst and the solid support are bound together via at least one of the rhodiums' axial positions. The compositions can be used in a number of reactions, including insertion reactions (e.g., C—H insertions, Si—H insertions, O—H insertions, and N—H insertions), cyclopropanation reactions, annulations (e.g., [3+2] annulations and [3+4] annulations), and ω,ω-diarylalkanoate synthesis. Methods for making the dirhodium catalyst compositions are also disclosed.
摘要:
Preparation of biologically active tropane derivatives of novel configurations. The compounds are prepared by decomposing vinyldiazomethanes in the presence of pyrroles to provide a bicyclic ring containing the basic tropane ring system which is then reacted with an aryl Grignard reagent in the presence of a copper (I) or (II) salt to provide 3-aryl-tropane derivatives.
摘要:
The disclosure relates to TAK1 inhibitors, compositions, and uses related thereto. In certain embodiments, the disclosure relates to compounds of formula (I), pharmaceutical compositions having a compound of formula (I), and methods of treating or preventing cancer by administering an effective amount of a pharmaceutical composition having a compound of formula (I) to a subject in need thereof.
摘要:
Disclosed are methods for alleviating symptoms of neuropsychiatric disorders using tetrahydropyridine derivatives bearing aromatic substituents. The method comprises administering to an individual a tetrahydropyridine derivative bearing aromatic substituents in an amount effective to alleviate symptoms of the neuropsychiatric disorder.
摘要:
Novel tropane ring system compounds useful for treatment of neurological disorders and for synthetic starting materials for production of cocaine analogs.